Jiaming Huang

Jiaming Huang

Auto-generated profile, based on publicly available information

Jiaming Huang

Dana-Farber Cancer Institute, Boston, MA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
TZTalal El Zarif
Talal El Zarif
Amin NassarAmin Nassar
Amin Nassar
EAElio Adib
Elio Adib
BFBailey G. Fitzgerald
Bailey G. Fitzgerald
JHJiaming Huang
Jiaming Huang
RNRafeh Naqash
Rafeh Naqash
PURPOSE: Compared with people living without HIV (PWOH), people living with HIV (PWH) and cancer have traditionally been excluded from immune checkpoint inhibitor (ICI) trials. Furthermore, there is a paucity of real-world data on the use of ICIs in PWH and cancer. METHODS: This retrospective study included PWH treated with anti–PD-1- or anti–PD-L1-based therapies for advanced cancers. Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS). Objective response rates (ORRs) were measured per RECIST 1.1 or other tumor-specific criteria, whenever feasible. Restricted mean survival time (RMST) was used to compare OS and PFS between matched PWH and PWOH with metastatic NSCLC (mNSCLC). RESULTS: Among 390 PWH, median age was 58 years, 85% (n = 331) were males, 36% (n = 138) were Black; 70% (n = 274) received anti–PD-1/anti–PD-L1 monotherapy. Most common cancers were NSCLC (28%, n = 111), hepatocellular carcinoma ([HCC]; 11%, n = 44), and head and neck squamous cell carcinoma (HNSCC; 10%, n = 39). Seventy percent (152/216) had CD4+ T cell counts ≥200 cells/µL, and 94% (179/190) had HIV viral load <400 copies/mL. Twenty percent (79/390) had any grade immune-related adverse events (irAEs) and 7.7% (30/390) had grade ≥3 irAEs. ORRs were 69% (nonmelanoma skin cancer), 31% (NSCLC), 16% (HCC), and 11% (HNSCC). In the matched mNSCLC cohort (61 PWH v 110 PWOH), 20% (12/61) PWH and 22% (24/110) PWOH had irAEs. Adjusted 42-month RMST difference was –0.06 months (95% CI, –5.49 to 5.37; P = .98) for PFS and 2.23 months (95% CI, –4.02 to 8.48; P = .48) for OS. CONCLUSION: Among PWH, ICIs demonstrated differential activity across cancer types with no excess toxicity. Safety and activity of ICIs were similar between matched cohorts of PWH and PWOH with mNSCLC.

1 January 2017 in Journal of Cancer
Verified
Journal Article
Open access
WWWei Wang
Wei Wang
CSChunliang Shang
Chunliang Shang
QDQiqiao Du
Qiqiao Du
DWDi Wu
Di Wu
YLYan-Chun Liang
Yan-Chun Liang
SYShuzhong Yao
Shuzhong Yao
Background & Aims: The long-term oncological outcome of Class I hysterectomy to treat stage IB1 cervical cancer is unclear. The aim of the present study was to compare the surgical and long-term oncological outcomes of Class I hysterectomy and Class III radical hysterectomy for treatment of stage IB1 cervical cancer (tumor ≤ 2 cm).

1 November 2021 in Contraception
Verified
Journal Article
Closed access
MRMaria I. Rodriguez
Maria I. Rodriguez
TMThomas Meath
Thomas Meath
JHJiaming Huang
Jiaming Huang
BDBlair G. Darney
Blair G. Darney
KMK. John McConnell
K. John McConnell